4/A: Herbalife CEO's SARs Exercise Price Corrected to $19.26

Herbalife Ltd. CEO Stephan Paulo Gratziani's Stock Appreciation Rights exercise price has been corrected to $19.26 from $10.51 in an amended SEC filing.

Summary

• Stephan Paulo Gratziani, Chief Executive Officer of Herbalife Ltd. (HLF), filed an amendment to a Form 4.
• The amendment was filed to correct the exercise price of Stock Appreciation Rights (SARs) previously reported.
• The corrected exercise price for 215,033 SARs is $19.26, up from the originally reported $10.51.
• These SARs were granted on February 25, 2026, under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.
• The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, contingent on continued service.
• The expiration date for these SARs is February 25, 2036.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development for the executive's potential compensation, as the corrected higher exercise price reduces the immediate 'in-the-money' value of the SARs. For the company, it's a neutral compliance correction.

Positives

• The grant of 215,033 Stock Appreciation Rights (SARs) aligns the CEO's incentives with shareholder value creation over the long term.

Negatives

• The correction of the exercise price from $10.51 to $19.26 means the SARs require a higher stock price appreciation to become 'in the money' or yield a profit for the executive, making them less immediately valuable than originally reported.

Future Outlook

The vesting schedule for the SARs extends through February 2029, indicating a continued incentive for the CEO to remain with the company and drive long-term performance.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity awards like SARs, is a standard practice across industries to align management interests with shareholder returns. The correction of an exercise price, while a compliance matter, highlights the importance of accuracy in regulatory filings.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a correction to an executive's compensation detail rather than a new grant or major financial event. It ensures accuracy in executive compensation disclosures.
• Employees: No direct impact mentioned.
• Executive (Stephan Paulo Gratziani): The higher exercise price reduces the potential immediate value of the SARs, requiring greater stock appreciation for a payout.

Next Steps

• The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service.

Key Dates

Recommendation

This filing is an amendment correcting the exercise price of executive Stock Appreciation Rights. It does not contain information significant enough to alter a seasoned investor's fundamental view or recommendation on Herbalife Ltd. stock. The correction itself is a compliance matter, and while the higher exercise price is less favorable for the executive, it does not materially impact the company's operational or financial outlook.

Keywords

Herbalife, HLF, Stephan Paulo Gratziani, Stock Appreciation Rights, SARs, Executive Compensation, SEC Form 4/A, Insider Trading, Equity Incentive Plan